CJC/IPA Protocol
Also known as: CJC-1295/Ipamorelin, CJC/Ipa
GHRH/GHRP Combination | Growth Hormone Optimization
Overview
A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms. CJC-1295 demonstrates 2-10 fold GH increases with 6-8 day duration, while Ipamorelin provides selective GH release without cortisol elevation.
Key benefits
- Sustained GH elevation (6-8 days from CJC-1295)
- Selective pulsatile release without cortisol suppression
- Complementary dual-pathway optimization
- Preservation of natural GH rhythm
- Enhanced muscle protein synthesis and recovery
Mechanism of action
CJC-1295 activates GHRH receptors via albumin-binding DAC technology for sustained elevation. Ipamorelin selectively activates ghrelin receptors (GHSR1a) without affecting ACTH/cortisol, preserving natural pulsatile GH patterns.
Molecular data
- Type
- Peptide combination (GHRH analog + GHS)
Sequence
N/A
Blend composition
What is in the vial, and in what proportion. Each component has its own reference page.
| Component | Amount | Ratio |
|---|---|---|
| CJC-1295 | 2 mg | 1 |
| Ipamorelin | 2 mg | 1 |
Total 4 mg per vial.
Indications
What the research community uses this compound for, with self-reported effectiveness.
Muscle Growth
Enhanced Protein Synthesis
Most effectiveGrowth hormone elevation supports muscle protein synthesis and nitrogen retention during training.
Improved Recovery
Most effectiveSustained GH patterns may accelerate muscle repair between exercise sessions.
Lean Mass Preservation
Most effectiveGH optimization helps maintain muscle during caloric restriction or aging.
Metabolic Health
Body Composition Support
EffectiveGrowth hormone promotes lipolysis while supporting lean tissue maintenance.
Metabolic Flexibility
EffectiveEnhanced GH patterns may improve glucose and fat utilization.
Anti-Aging
Sleep Quality Enhancement
ModerateEvening GH peaks align with deeper, more restorative sleep patterns.
Tissue Regeneration
ModerateSustained GH elevation supports skin elasticity and connective tissue health.
Recovery
Accelerated Healing
ModerateGrowth hormone supports tissue repair and recovery from exercise or injury.
Joint Health
ModerateEnhanced collagen synthesis supports joint and connective tissue integrity.
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Injectable
Subcutaneous administration optimal for bioavailability; available as blended vials or separate formulations.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| General Health Optimization | 200mcg each (0.2mL if 1mg/mL) | Once daily | SubQ |
| Performance Enhancement | 250mcg each (0.25mL if 1mg/mL) | Once daily | SubQ |
| Recovery Optimization | 300mcg each (0.3mL if 1mg/mL) | Once daily | SubQ |
| Conservative Approach | 150mcg each (0.15mL if 1mg/mL) | 5 days per week | SubQ |
Preparation
You will need
- Bacteriostatic water (2-4mL)
- Insulin syringes (0.3-1mL capacity)
- Alcohol swabs for sterilization
Steps
- BLENDED: Add 2mL bacteriostatic water to create ~2mg/mL concentration
- SEPARATE: Add 2mL water to each vial for 1mg/mL per peptide
- Draw 0.2-0.3mL for 200-300mcg dosing
- Mix equal volumes or inject at different sites
- Administer 2-3 hours post-meal, 30-60 minutes before bed
- Rotate subcutaneous sites (abdomen, thigh, upper arm) daily
Work out the water volume and syringe units in the reconstitution calculator →
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
Synthetic HGH
AvoidRedundant mechanisms may cause excessive GH suppression of natural pulsatile release.
MK-677
MonitorBoth affect GH pathways; monitor for excessive GH elevation and insulin sensitivity changes.
Insulin
MonitorGH affects insulin sensitivity; diabetic users require glucose monitoring and insulin adjustments.
Thyroid Medications
MonitorSpace 4+ hours from GH secretagogues due to absorption and metabolic interactions.
Corticosteroids
MonitorMay blunt GH response; higher doses or alternative timing may be necessary.
BPC-157
CompatibleNo known interactions; different mechanisms (GH optimization vs. tissue repair signaling).
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Week 1-2
Improved sleep depth and quality; increased dream vividness
- Week 3-4
Enhanced exercise recovery; reduced muscle soreness; improved energy
- Week 6-8
Gradual body composition changes; improved skin quality; general well-being
- Week 8-12
Optimized benefits plateau; individual responses vary significantly
- Post-Cycle
Benefits persist several weeks due to improved sleep and recovery patterns
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Water retention and joint swelling
- Carpal tunnel syndrome (numbness/tingling)
- Mild blood glucose elevation
- Injection site irritation with improper rotation
Stop signs — stop and seek advice
- Persistent joint pain or swelling indicating fluid retention
- Significant blood glucose changes or diabetic control issues
- Unusual fatigue, lethargy, or mood deterioration
- Injection site infections or persistent reactions
- Numbness or tingling in hands/feet
- Signs of accelerated tumor growth if cancer history exists
Contraindications
- Cancer history or active malignancy
- Severe diabetes requiring tight glucose control
- Carpal tunnel syndrome or nerve compression disorders
Monitoring
- Regular bloodwork to monitor IGF-1 levels
- Blood glucose monitoring if diabetic
- Injection site assessment for lipodystrophy
- Overall health markers and tolerability
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- Standard format labeling: '10mg total: 5mg CJC-1295 + 5mg Ipamorelin'
- 1:1 ratio maintenance between peptides for optimal effects
- Clear reconstitution without particles or cloudiness
- Certificate of Analysis with individual peptide purities
- Proper cold chain with cold packs and immediate refrigeration
Warning signs
- Format selection: Beginners prefer separate vials for tolerance testing
- Blended format offers convenience but limits dose adjustment
- Combination protocols lack peer-reviewed clinical validation
Stop signs — don't use
- Damaged packaging or missing refrigeration
- Heat exposure during shipping
- Lack of Certificate of Analysis documentation
Recent research
Newer papers and trial readouts on file for this compound, with source and date.
June 2024 · AIDS
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors
Recent GHRH-analog data: tesamorelin (a related GHRH analog) reduced visceral and hepatic fat in HIV patients on modern antiretrovirals, supporting continued relevance of the GHRH pathway.
July 2025 · Clinical Endocrinology
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin in HIV-associated lipodystrophy: A meta-analysis
Meta-analysis of five RCTs of a GHRH analog confirmed significant visceral adipose tissue reduction, reinforcing the therapeutic value of the GHRH signaling axis targeted by CJC-1295.
References
Primary literature and clinical-trial data informing this entry.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, et al. · Journal of Clinical Endocrinology & Metabolism · 2006
Single CJC-1295 injection produced dose-dependent 2-10 fold GH increases for 6+ days and 1.5-3 fold IGF-1 increases for 9-11 days; estimated half-life 5.8-8.1 days.
Ipamorelin, the first selective growth hormone secretagogue
Raun K, Hansen BS, Johansen NL, et al. · European Journal of Endocrinology · 1998
Ipamorelin is the first GHRP-receptor agonist with selectivity for GH release similar to GHRH; does not release ACTH or cortisol even at doses over 200-fold the ED50 for GH.
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M, Frohman LA · Journal of Clinical Endocrinology & Metabolism · 2006
CJC-1295 preserves pulsatile GH secretion with unaltered pulse frequency and magnitude; basal GH levels increased 7.5-fold, mean GH 46%, and IGF-1 45%.
Ghrelin and growth hormone secretagogues potentiate GH-releasing hormone-induced cAMP production in cells expressing transfected GHRH and GH secretagogue receptors
Cunha SR, Mayo KE · Endocrinology · 2002
GHS potentiate GHRH-induced cAMP in a dose-dependent manner requiring co-expression of both receptors, providing the cellular basis for GHRH/GHRP synergy.
Last updated . How this page was sourced is described in the methodology.